Paracrine

Executive Summary

Paracrine is a private biotechnology company at the forefront of advanced wound care, combining autologous regenerative cell therapy with a proprietary AI platform. Its core technology, Stromal Vascular Therapy (SVT), utilizes a patient's own fat-derived cells to treat chronic wounds, achieving high closure rates. The AiPara Suite™ leverages machine learning to predict outcomes, select optimal patients, and monitor healing, aiming to make advanced wound care scalable and cost-effective. Founded in 2016 and headquartered in San Diego, Paracrine addresses a significant unmet need in the wound care market, which affects millions of patients globally. The company is poised to disrupt the wound care space by offering a personalized, cell-based therapy that could reduce healthcare costs and improve patient outcomes. Paracrine's immediate focus is likely on completing clinical trials to support regulatory submissions and securing partnerships for commercialization. With a strong technological foundation and a growing need for effective chronic wound treatments, Paracrine has the potential to become a leader in regenerative medicine. Key upcoming catalysts include pivotal clinical data readouts, potential FDA designations, and strategic alliances that could accelerate market access.

Upcoming Catalysts (preview)

• Q4 2026Pivotal Phase 2/3 Trial Data Readout for SVT in Chronic Wounds65% success
• Q2 2027FDA Breakthrough Therapy Designation or Fast Track Status55% success
• H1 2027Strategic Partnership or Licensing Deal with Major Wound Care Company50% success